newsfilter
← Latest News
GlobeNewswire·

I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first